# Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

> **NCT00517517** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alachua Government Services, Inc.** · enrollment: 110 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation

## Key facts

- **NCT ID:** NCT00517517
- **Lead sponsor:** Alachua Government Services, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2007-09
- **Final completion:** 2008-02
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517517, "Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00517517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*